Ellen Schanknecht
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ellen Schanknecht has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Ava Bachari
The Pangenomics Lab, School of Science, RMIT University, Bundoora, VIC 3083, Australia
1 shared publication - Kanika Singh
The Pangenomics Lab, School of Science, RMIT University, Bundoora, VIC 3083, Australia
1 shared publication - Nazim Nassar
School of Science, RMIT University, Bundoora West Campus, Melbourne, Vic 3083, Australia
1 shared publication - Nitin Mantri
The Pangenomics Laboratory, School of Science, RMIT University, Bundoora, VIC 3083, Australia
1 shared publication - Roby Zomer
MGC Pharmaceuticals Limited, West Perth, WA 6005, Australia
1 shared publication - Srinivasa Reddy Telukutla
Accelerator for Translational Research in Clinical Trials (ATRACT) Centre, School of Health and Biomedical Sciences, STEM College, RMIT University, Melbourne, VIC 3083, Australia
1 shared publication
Latest Publications
- Open Access
The Pathophysiology and the Therapeutic Potential of Cannabinoids in Prostate Cancer
Prostate cancer is the second most frequently occurring cancer diagnosed among males. Recent preclinical evidence implicates cannabinoids as powerful regulators of cell growth and differentiation. In this review, we focused on studies that demonstrated anticancer effects of cannabinoids and their possible mechanisms of action in prostate cancer. Besides the palliative effects of cannabinoids, research from the past two decades has demonstrated their promising potential as antitumor agents in a wide variety of cancers. This analysis may provide pharmacological insights into the selection of specific cannabinoids for the development of antitumor drugs for the treatment of prostate cancer.
Open AccessThe Pathophysiology and the Therapeutic Potential of Cannabinoids in Prostate Cancer
Prostate cancer is the second most frequently occurring cancer diagnosed among males. Recent preclinical evidence implicates cannabinoids as powerful regulators of cell growth and differentiation. In this review, we focused on studies that demonstrated anticancer effects of cannabinoids and their possible mechanisms of action in prostate cancer. Besides the palliative effects of cannabinoids, research from the past two decades has demonstrated their promising potential as antitumor agents in a wide variety of cancers. This analysis may provide pharmacological insights into the selection of specific cannabinoids for the development of antitumor drugs for the treatment of prostate cancer.